Kidney Cancer Research Consortium Efforts May Improve Treatment Outcomes

Commentary
Video

Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.

In a collaboration with KidneyCAN, CancerNetwork® spoke with Eric Jonasch, MD, about the Kidney Cancer Research Consortium’s overarching goal to advance the treatment of patients with kidney cancer through a collaborative effort to refine the field’s therapeutic strategies to improve outcomes.

Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine, and the director of the von Hippel Lindau Center at The University of Texas MD Anderson Cancer Center, highlighted key principles driving the consortium’s mission of improving treatment outcomes in this patient population. Specifically, he described how novel treatment agents, innovative clinical trial designs, correlative studies incorporating biopsies and circulating biomarker analyses, and new technologies may help with targeting tumors more optimally.

KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. Learn more about KidneyCAN’s mission and work here.

Transcript:

The question is: what are the missions and goals of the Kidney Cancer Research Consortium? What is my role? I’m the principal investigator of this effort, and it’s a Department of Defense [DoD]–funded grant whose mission is to improve the treatment of patients with renal cell carcinoma. We’re achieving this by developing a network of clinical trial centers across the country who have expertise, both from the development as well as from the execution perspective. We want to do the clinical trials that industry wouldn’t do otherwise and do the trials that are going to allow us to gain knowledge faster than other trials.

We do this by, number one, using novel agents. Number two [is] using more efficient and innovative clinical trial designs. Number three [is] incorporating correlative studies, including biopsies and other various circulating biomarker analyses, that allow us to get smarter faster when we perform these studies. Lastly, with the tissue that we acquire from these patients, we have some cutting-edge technologies that allow us to look at the tumor in ways that we’ve never been able to look at before. That allows us to see what the cancer cells are doing relative to the immune cells; are the tumor cells happy or unhappy with regards to the treatments we’re providing? How are the immune cells doing? This just gets us closer to being able to come up with more refined ways of improving our treatments.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content